Trial Profile
A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary) ; Pembrolizumab (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Pharyngeal neoplasms; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Apr 2023 Results published in the Nature Medicine
- 23 Feb 2023 Planned End Date changed from 5 Jan 2023 to 5 Jan 2025.
- 23 Feb 2023 Planned primary completion date changed from 5 Jan 2023 to 5 Jan 2024.